Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC grew its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 2.3% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 764,931 shares of the medical equipment provider's stock after acquiring an additional 17,396 shares during the period. Stephens Investment Management Group LLC owned about 0.34% of Hologic worth $47,250,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Allworth Financial LP raised its position in shares of Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Raiffeisen Bank International AG purchased a new stake in Hologic during the 4th quarter valued at about $49,000. West Financial Advisors LLC purchased a new stake in Hologic during the 1st quarter valued at about $50,000. Finally, Covestor Ltd grew its stake in Hologic by 49.3% during the 4th quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after acquiring an additional 341 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Insider Buying and Selling at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the acquisition, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the company from $60.00 to $80.00 in a research note on Wednesday. Royal Bank Of Canada dropped their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Evercore ISI increased their price target on shares of Hologic from $62.00 to $68.00 and gave the company an "in-line" rating in a research note on Tuesday, July 8th. Raymond James Financial reissued an "outperform" rating and issued a $71.00 price target (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Finally, Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $78.75.

Hologic Price Performance

Hologic stock opened at $65.72 on Friday. The firm has a market cap of $14.65 billion, a PE ratio of 27.73, a price-to-earnings-growth ratio of 2.41 and a beta of 0.55. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The company's 50 day moving average is $61.55 and its two-hundred day moving average is $63.48.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm's quarterly revenue was down 1.2% on a year-over-year basis. During the same period in the prior year, the business earned $1.03 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.